The Peptide Field. AOD-9604: approval and evidence record.

Editorial review: 2026-07-23. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/aod-9604

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=aod-9604#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: No FDA-approved AOD-9604 drug product

Exact product limits: A study product, an injection, and a skin product are not automatically the same. Oral clinical-study material, compounded injections, and transdermal products are not interchangeable. FDA found route-specific evidence gaps.

Human outcomes: Limited. Older obesity studies exposed hundreds of participants, but the evidence did not establish an approved weight-loss use.

Body effects in people: Limited. FDA found insufficient pharmacokinetic and pharmacodynamic information for proposed uses and routes.

What the evidence shows: FDA reviewed several obesity studies in people, including larger oral programs, and documented the available adverse-event reporting. This confirms that people received it in studies. It does not establish a benefit.

What remains unknown: The record does not establish meaningful weight loss, long-term benefit, or safety for injectable or transdermal products. FDA found no human information for some proposed routes of use.

Safety limits: An incomplete development program does not provide instructions for self-treatment. No sourcing, reconstitution, injection, or weight-loss regimen is provided.

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration. FDA briefing document for AOD-9604-related bulk drug substances. 2024. Accessed 2026-07-23. https://www.fda.gov/media/183584/download

U.S. Food and Drug Administration. Bulk drug substances that may present significant safety risks. 2026. Accessed 2026-07-23. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

U.S. Food and Drug Administration. Sterile compounded AOD-9604 recall for lack of sterility assurance. 2021. Accessed 2026-07-23. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/innoveix-pharmaceuticals-inc-issues-voluntary-recall-all-sterile-compounded-drug-products-due-lack-0

World Anti-Doping Agency. 2026 Prohibited List. 2026. Accessed 2026-07-23. https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list

Keep the limits, review date, and sources with this record. Check the current source for changes.